Abstract 169TiP
Background
Patients with microsatellite instability (MSI) solid tumors are equisitely sensitive to immune-checkpoint inhibitors (ICIs). The pharmacokinetics data as well as early efficacy data have shown that low dose- ICIs (LD-ICIs) may have similar efficacy to standard dose in MSI solid tumors. While standard dose pembrolizumab as well as the combination of nivolumab and ipililumab are effective therapeutic options in advanced colorectal cancers (mCRC), it may not be feasible in a majority of patients in low income countries (LICs) and lower middle income countries (LMICs). With this background, the current study aims to evaluate the efficacy of LD-Nivolumab in mCRC.
Trial Design
The CLOUD study is planned as a single-arm, open-label, prospective, phase 2 superiority study. Adults aged >= 18 years with adequate end-organ function and Eastern Cooperative Oncology Group performance status (PS) 0-1 diagnosed with treatment naïve unresectable or metastatic colorectal adenocarcinoma (patients could have received previous adjuvant chemotherapy for colorectal cancer if the earlier treatment had been completed at least 6 months before enrolement) with MSI status (on Polymerase Chain reaction or Next Generation Sequencing) or deficient mismatch repair (dMMR) protein status on biopsy will be considered for enrolment. Accrued patients will receive nivolumab 40 mg IV every 3 weekly for 6 months and then 6 weekly for next 6 months (maximum of 12 months or till disease progression, whichever is earlier). The study is planned in two stages. The null hypothesis is that the true progression free survival is 35% at 12 months with chemotherapy, which will be tested against a one-sided alternative. In the first stage, 20 patients will be accrued, and if there are 7 or fewer patients who are progression free at 12 months in these 20 patients, the study will be stopped. Otherwise, 27 additional patients will be accrued for a total of 47 patients. The null hypothesis will be rejected if 21 or more have progressed within 12 months in the entire cohort. This design yields a type I error rate of 0.1 and power of 90 when the progression free survival at 12 months is 55%. Assuming a loss to follow up or attrition rate of 10%, the total sample size of the study 52 patients.
Clinical trial identification
CTRI/2024/01/061681, Registered on: 22/01/2024.
Legal entity responsible for the study
Tata Memorial Hospital.
Funding
TMC Research Administration Council (TRAC), Tata Memorial Centre.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session